| Position | Action |
|---|---|
| Trim 30-40% of SPCX exposure at market ($114-115) into current post-bounce strength | TRIM 30-40% |
| Stage second tranche into $118-121 Bollinger midline zone | ADD TRANCHE at $118-121 |
| Residual position held with closing-basis invalidation at $122-123 | HOLD residual ~40-50% |
| If <20% trimmed by EOD session 1 | MARKET-SELL balance |
| Re-engagement after catalyst clearance and technical confirmation | LIMIT ADD up to 50% of original size (capped at half) |
SPCX at ~$115 represents a generational entry point as smart money accumulates, technical indicators signal a basing pattern (not breakdown), and the company has demonstrated deep structural demand capable of absorbing massive supply events while beating consensus on all key metrics.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 116.13 | neutral |
| close_50_sma | 142.29 | bearish |
| close_200_sma | 142.29 | — |
| RSI (14) | 41.27 | neutral |
| MACD | –8.21 | bullish |
| MACD Signal | –9.02 | — |
| MACD Histogram | +0.80 | bullish |
| Bollinger Upper Band | 142.90 | bearish |
| Bollinger Middle Band | 121.45 | neutral |
| Bollinger Lower Band | 99.99 | bullish |
| ATR (14) | 10.34 | bearish |
| VWMA | 115.00 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Underweight: Trim 30-40% into strength at $114-115, stage second tranche at $118-121, hold residual with $122-123 closing-basis stop
Underweight with corrected execution, not maximalist Sell. Bear case dominant on 62x forward P/E pricing immaculate execution, 143% float expansion (638.9M to 1,550.4M shares), Q1 2026 net losses widening 8x YoY with R&D +126% YoY, price 19.2% below 50 SMA at $142.29 with MACD at -8.21. However, three prior Underweight calls (+5.7%, +9.4%, +6.1%) lost to reflexive bounces — ATR-adjusted R/R insufficient for maximalist spot-Underweight into Friday NFP binary catalyst. Split trim into two tranches with closing-basis stop at $122-123 (not trader's $125 intraday stop, which fails ATR-compatibility test against $10.34 ATR). Re-engagement requires catalyst clearance, technical confirmation above $121.45 on volume, RSI >50, and close above 50 SMA at $142.29 — capped at half original size.
When: Two consecutive closes above $121.45 on above-average volume, RSI >50 and holding, close above 50 SMA at $142.29, after NFP/NVIDIA catalyst clearance
Then: LIMIT ADD up to 50% of original size
Earnings beat consensus on every material metric despite post-earnings selloff
↩ rebuts: “Bear interpretation of earnings as 'terrible'”
· concedes: SPCX is volatile, capital-intensive, and richly valued; The stock recently experienced a 49% drawdown from $225.64 to $108.37; Forward P/E is 62x and EV/Revenue is ~79x are extreme metrics; EV/EBITDA at ~387x is 'extreme' if growth stalls; Bear case on valuation assumes growth thesis is wrong
SPCX at $115 is not a generational entry point but a bear trap—a $1.514T market cap built on 62x forward P/E, -$14.1B annual FCF burn, accelerating R&D, and a chart with all major moving averages overhead—with more unlock supply coming, the MACD still deeply negative, and the stock just 10% above its 52-week low.
· concedes: The competitive moat is real; The long-duration AI/space story is real; The unlock didn't crash the stock on day one; The MACD histogram did turn positive (+0.80); RSI did show divergence (28.22 to 41.27); The ATR did cool 35%
→ vs conservative: Holding because Cathie Wood is buying and Morgan Stanley called it a generational compounder ignores that ARK flow is trivial and the MS thesis is a 5-10 year call irrelevant to near-term $99-145 range
→ vs conservative: Lockup absorption narrative misses that 143% float expansion with low-cost-basis insiders slowly bleeding supply creates a 'slowly bleeding out at $108' story by October, not recovery
→ vs neutral: 'Mixed signals, wait for confirmation' is the consensus trap — by the time RSI breaks 50 and holds on two closes above 121.45 with volume, stock will be at $135 chasing, or support at 108 breaks
Support: 99.99 · 108 · 115 · 105.11 | Resistance: 116.13 · 121.45 · 142.29 · 142.9
SPCX is in a structural downtrend with price (114.92) sitting ~19.2% below the 50 SMA at 142.29, which remains the major overhead resistance level. Short-term indicators show early bullish momentum signals: RSI has formed a textbook bullish divergence (41.27 vs 28.22 swing low on 7/20) and MACD histogram printed its first positive reading (+0.80) since early July, indicating a momentum reset rather than trend confirmation. The August basing pattern with 144M–250.8M shares of two-way volume suggests absorption/distribution rather than directional conviction. The 200 SMA value of 142.29 is flagged as unreliable due to insufficient price history (<200 sessions). ATR of 10.34 implies ~9% daily-range volatility, warranting conservative position sizing. Critical support is 99.99 (Bollinger lower band); a daily close below this would invalidate the basing thesis. Structural trend change requires a sustained close above 142.29.
Market Cap
$1,514.85B
Revenue (TTM)
$19.30B
Gross Profit (TTM)
$9.42B
EBITDA (TTM)
$3.95B
Net Income (TTM)
-$9.36B
EPS (TTM)
-$1.10
Forward EPS
$1.85
Forward P/E
62.02
P/B
11.90
Profit Margin
-45.0%
Operating Margin
-41.6%
Gross Margin
48.8%
Debt/Equity
73.60
Current Ratio
1.22
52W High
$225.64
52W Low
$104.83
50/200-day Avg
$144.53
Total Revenue (2025)
$18,674M
Gross Profit (2025)
$9,223M
R&D (2025)
$8,643M
Net Income (2025)
-$4,937M
Diluted EPS (2025)
-$0.51
D&A (2025)
$6,701M
Total Assets
$102.09B
Cash + ST Investments
$23.68B
Total Debt
$30.60B
Stockholders' Equity
$41.58B
Net Debt
$14.41B
Working Capital
$5.30B
Deferred Revenue
$13.24B
Construction in Progress (CIP)
$14.05B
Net PP&E
$55.06B
Operating CF (2025)
$6.79B
CapEx (2025)
-$20.91B
Free Cash Flow (2025)
-$14.12B
Equity Issued (2025)
$18.81B
Debt Issued (2025)
$16.06B
Revenue CAGR (3yr)
~34%
Gross Margin (2025)
49.4%
Operating Margin (2025)
-11.1%
R&D/Revenue (2025)
46.3%
Strengths
Concerns
SPCX operates as a high-growth, capital-intensive aerospace company with TTM revenue of $19.30B but deep reported losses of -$9.36B driven by aggressive R&D investment ($8.64B in 2025, +149.5% YoY) and massive capex ($20.91B). The balance sheet shows $102.09B in total assets funded by $30.60B debt and $18.81B equity issuance, with $23.68B in liquid assets providing runway. Analysts expect a dramatic turnaround with forward EPS of $1.85 (vs trailing -$1.10), though the 62x forward P/E and $1.515T market cap leave little room for execution error.